These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31491493)

  • 1. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
    Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson's rats.
    Zhang XR; Zhang ZR; Chen SY; Wang WW; Wang XS; He JC; Xie CL
    Aging (Albany NY); 2019 Dec; 11(24):12315-12327. PubMed ID: 31891566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
    Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
    Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa-Induced Dyskinesia
    Wang WW; Zhang XR; Lin JY; Zhang ZR; Wang Z; Chen SY; Xie CL
    Front Pharmacol; 2019; 10():660. PubMed ID: 31275144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
    Lanza K; Centner A; Coyle M; Del Priore I; Manfredsson FP; Bishop C
    Exp Neurol; 2021 Feb; 336():113534. PubMed ID: 33249031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
    J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
    Ahmed MR; Bychkov E; Kook S; Zurkovsky L; Dalby KN; Gurevich EV
    Exp Neurol; 2015 Apr; 266():42-54. PubMed ID: 25687550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
    Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J
    Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677
    [No Abstract]   [Full Text] [Related]  

  • 13. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
    Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y
    Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
    Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
    Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
    Engeln M; Bastide MF; Toulmé E; Dehay B; Bourdenx M; Doudnikoff E; Li Q; Gross CE; Boué-Grabot E; Pisani A; Bezard E; Fernagut PO
    Biol Psychiatry; 2016 Mar; 79(5):354-361. PubMed ID: 25146322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
    Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.